Ionis Stock Plunges 26% After It Cuts Tryngolza's Sales Forecast To About $50 Million

The drug's slower launch prompted the cut, but Ionis kept its overall revenue outlook at $875–900 million.

Share
Ionis Stock Plunges 26% After It Cuts Tryngolza's Sales Forecast To About $50 Million

Ionis Pharmaceuticals, which develops RNA-targeted medicines for serious diseases, plunged 25.67% to $29.30 in Monday trading as of 9:42 a.m. ET, losing $1.7 billion in market value after cutting its Tryngolza sales forecast to approximately $50 million. The earnings release furnished with its SEC filing tied the forecast cut to the drug's slower launch, while detailed results published over the weekend added to the picture of an earlier heart-drug setback.

Tryngolza Slows, Dawnzera Grows

Ionis had forecast $100–110 million in Tryngolza sales for 2026. Third-quarter sales came in at $9 million, compared with $32 million a year earlier.

The company kept its 2026 revenue outlook at $875–900 million. Dawnzera sales reached $37 million in the quarter, compared with $1 million a year earlier.

Ionis sells both medicines itself in the United States. Its seven marketed medicines also include WAINUA, SPINRAZA, QALSODY, TEGSEDI and WAYLIVRA. It shares U.S. commercialization of WAINUA with AstraZeneca and uses partners including Biogen, Sobi, Otsuka and PTC Therapeutics to sell other medicines across various regions.

Pelacarsen's Earlier Setback

Pelacarsen, discovered by Ionis and developed in partnership with Novartis, did not reduce major cardiovascular events, including heart attacks and strokes, according to detailed trial results published over the weekend.

Novartis had announced the failure of the late-stage trial in September. The weekend findings supplied detail on that previously announced result.

Ionis focuses on neurology, cardiometabolic diseases and selected conditions with high unmet need. Its development portfolio includes three wholly owned medicines and six partnered medicines in late-stage testing. The company reported $944 million in revenue for 2025 and ended that year with $2.7 billion in cash, cash equivalents and short-term investments.

A Slide Before Monday's Plunge

Ionis entered Monday with a 10% decline over the previous month. At Friday's close, its shares were 54% below their highest close of the past year.

In Monday trading as of 9:42 a.m. ET, Ionis's market value stood at $4.87 billion. The stock was on pace for its biggest one-day decline in at least 274 trading sessions.

Sources

More on Ionis Pharmaceuticals

All Ionis Pharmaceuticals (IONS) coverage →